Welcome to our dedicated page for IN8bio news (Ticker: INAB), a resource for investors and traders seeking the latest updates and insights on IN8bio stock.
IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biotechnology company pioneering the development of novel therapies aimed at treating various cancers. Using allogeneic, autologous, and genetically modified gamma-delta T cells, IN8bio is revolutionizing cancer treatment. The company’s mission is to create groundbreaking therapies that harness the power of the body’s immune system to target and destroy cancer cells.
IN8bio's robust portfolio includes several promising product candidates:
- INB-400: Aimed at treating newly diagnosed glioblastoma (GBM), this product is currently in a Phase 2 clinical trial.
- INB-100: Designed for patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, this therapy is under Phase 1 clinical trials.
- INB-200: Another promising candidate targeting GBM, it has shown encouraging preliminary clinical data at the 2024 ASCO Annual Meeting.
- Additional products, like INB-300 and INB-500, are in various stages of development targeting both solid and liquid tumors.
Recently, IN8bio disclosed significant advancements in the treatment of GBM, utilizing their innovative gamma-delta T cell-based adoptive cellular therapy. A peer-reviewed publication highlighted the strategy and future direction of their novel treatment methods.
Financially, IN8bio extends its cash runway into 2025, bolstered by additional capital from a private placement in December 2023. The company continues to pursue more funding to advance its clinical trials and achieve its milestones.
IN8bio's groundbreaking work has garnered attention in the biotech field, especially for its genetically modified gamma-delta T cells, which are the first to be advanced into clinical trials. The company’s approach shows great potential in improving progression-free survival (PFS) and overall survival (OS) rates for GBM and other cancers.
For investors and stakeholders, IN8bio provides exciting opportunities as it moves towards commercializing its therapies, aiming to address significant unmet medical needs in oncology. For more information, please visit IN8bio.
News
Rhea-AI Summary
IN8bio, Inc. (INAB) reported positive results from Phase 1 studies of INB-100 in leukemia and INB-200 in GBM, showcasing durable remissions and extended progression-free survival. The company closed a private placement, securing $14.4 million in gross proceeds, strengthening its financial position. Dr. Corinne Epperly joined the Board of Directors. IN8bio highlighted upcoming pipeline milestones and events, including Phase 2 studies and potential IND applications. Financially, R&D expenses increased due to program advancements, while G&A expenses decreased. The company reported a net loss of $7.6 million for Q4 2023 and had a cash position of $21.3 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Summary
IN8bio, Inc. (INAB) presents new preclinical data on its non-signaling gamma-delta T cell CAR platform targeting CD-33 and CD-123 at the AACR Annual Meeting. The platform shows promise in selectively targeting cancer cells while sparing healthy tissue, potentially addressing 'undruggable' tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
-
Rhea-AI Summary
IN8bio, Inc. (INAB) CEO to present at investor conferences in March, showcasing innovative gamma-delta T cell therapies. Webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
Rhea-AI Summary
IN8bio, Inc. (NASDAQ: INAB) announces a publication in Frontiers in Immunology discussing their novel gamma-delta T cell therapy for glioblastoma. The therapy, DeltEx Drug Resistance Immunotherapy (DRI), aims to enhance the immune response against GBM while minimizing toxicity to healthy tissues. IN8bio's Phase 1 trial shows promising results with a possible improvement in progression-free survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
IN8bio, Inc. (NASDAQ: INAB) has announced positive data from clinical trials of its innovative gamma-delta T cell therapies INB-100, INB-200, and INB-400, with 100% durable complete remissions in leukemia patients and extended progression-free survival in glioblastoma multiforme patients. The company also closed a private placement, securing a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.1%
Tags
-
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) presents positive updated data from its Phase 1 investigator-sponsored trial of INB-100 at the 65th ASH Annual Meeting & Exposition. 100% of treated leukemia patients remain alive, progression-free, and in durable complete remission. INB-100 shows the first-ever durable persistence of an allogeneic cellular therapy, with expansion and persistence of allogeneic gamma-delta T cells 365 days post-administration. The trial is being expanded, and additional data is expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.73%
Tags
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) has closed an initial round of fundraising, securing $14.4 million with the potential for an additional $32.5 million at increasing valuations. The company plans to use the proceeds to accelerate the development of its gamma-delta T cell therapies, extending its cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.29%
Tags
-
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) appoints Corinne Epperly, MD, MPH, an internationally recognized immuno-oncology and cell therapy executive, to its Board of Directors. Dr. Epperly brings 20 years of experience in innovative immunotherapies for solid and hematological cancers, with a deep background at leading organizations such as Bristol Myers Squibb, Iovance Biotherapeutics, the National Cancer Institute, Goldman Sachs, and most recently CARGO Therapeutics. She will provide guidance on strategic, operational, scientific, and clinical matters related to the Company’s pipeline of gamma-delta T cell therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
-
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) to host conference call to review INB-100 trial data presented at ASH 65th Annual Meeting, featuring clinical thought leader Michael Bishop, MD, on December 12, 2023 at 8:30 am ET. The trial investigates allogeneic gamma-delta T cells for hematologic malignancies post bone marrow transplantation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.22%
Tags
Rhea-AI Summary
IN8bio, Inc. (Nasdaq: INAB) presented data at the SNO 28th Annual Meeting demonstrating that all patients treated with INB-200 who completed mandated doses have exceeded a progression-free survival (PFS) of seven months, with one patient in Cohort 2 remaining alive and progression free past 28.5 months. The Phase 1 trial assesses the safety and preliminary efficacy of the addition of DeltEx DRI gamma-delta T cells to standard-of-care maintenance therapy for newly diagnosed glioblastoma (GBM) patients. The results show the potential of IN8bio’s DeltEx DRI gamma-delta T cells for treating GBM patients and potentially other solid tumor cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
FAQ
What is the current stock price of IN8bio (INAB)?
The current stock price of IN8bio (INAB) is $0.3215 as of November 20, 2024.
What is the market cap of IN8bio (INAB)?
The market cap of IN8bio (INAB) is approximately 22.5M.
What does IN8bio, Inc. do?
IN8bio, Inc. is a biotechnology company focused on developing novel cancer therapies using allogeneic, autologous, and genetically modified gamma-delta T cells.
What are the main products of IN8bio?
IN8bio's main products include INB-400 for glioblastoma, INB-100 for high-risk leukemias, and other candidates like INB-200, INB-300, and INB-500.
What recent advancements has IN8bio made?
IN8bio recently highlighted advancements in GBM treatment using gamma-delta T cell-based adoptive cellular therapy, showing promising clinical data at the 2024 ASCO Annual Meeting.
How is IN8bio funded?
IN8bio’s operations are funded through private placements and capital investments, extending their financial runway into 2025.
What is the significance of IN8bio's gamma-delta T cells?
IN8bio's gamma-delta T cells are the first genetically modified cells advanced into clinical trials, showing potential in improving cancer treatment outcomes.
How can I learn more about IN8bio’s clinical trials?
Details about IN8bio’s clinical trials can be found on their website and clinical trial registries like clinicaltrials.gov.
What is INB-400?
INB-400 is a Phase 2 clinical trial product targeting newly diagnosed glioblastoma, showing promising preliminary data in extending progression-free survival.
Where is IN8bio headquartered?
IN8bio, Inc. is headquartered in New York, NY.
Who can I contact for investor relations?
For investor relations, contact Lee M. Stern at Meru Advisors via email at lstern@meruadvisors.com.
How does IN8bio contribute to cancer research?
IN8bio contributes by developing cutting-edge therapies that leverage the body's immune system to target cancer cells, advancing both scientific and clinical understanding of gamma-delta T cell functions.
IN8bio, Inc.
Nasdaq:INAB
INAB Rankings
INAB Stock Data
22.49M
55.10M
21.56%
46.46%
1.38%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States of America
NEW YORK